Montreal AI startup with a touted advisor licenses its 'few-shot' platform to Repare for synthetic lethality molecules
The rise of AI in drug discovery has presented a buffet of tasty options for drugmakers to identify better molecules for hard-to-hit targets. That promise is mixed, to say the least, but startups like Montreal’s Valence Discovery think they’ve cracked the code — and at least one small biotech is convinced.
Valence, a recently uncloaked AI startup specializing in deep learning in drug discovery, has licensed its tech to Canada’s Repare Therapeutics to identify effective synthetic lethality molecules, the companies said Wednesday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.